Transforming bone infection treatment
through innovative drug delivery platform
About us
Moroxite I have discovered an innovative way of treating bone infection by exploring the potential of hydroxyapatite particles being pre-functionlized with specific antibiotics to eradicate reservoirs of bacteria. Nano-sized particles of hydroxyapatite can enter cells and release the antibiotics intracellularly.
Locally implanted HA nano and micro sized particles can act as a trojan horse which opens groundbreaking new bone infection treatment by systemically sending and repeatedly reloading with antibiotics with accretion to particulate hydroxyapatite.
Our Board
Lars Lidgren
Lidgren is M.D., PhD and a senior Professor at the internationally renowned Department of Orthopaedics, Clinical Sciences Lund, Sweden, and a Honorary Professor at Copenhagen University. He is also a serial entrepreneur who has founded listed medtech and healthcare companies like Scandimed (Biomet), Bonesupport and Safeture.
Semmy Rülf
Rülf has extensive experience in the med-tech and IT industry. He has worked at the Swedish Chamber of Commerce, IFÖ, Facit – Eriksson Information and was the CEO of Axis Communications. He started ProstaLund and has been regional director at VisitSweden. Currently Chairman of Moroxite F and Senior Advisor in Igelösa Life Science.
News
Study published in Journal of Bone and Joint Infection
January 2023
TERM group at LU has published a study reporting that systemic rifampicin shows accretion to locally implanted hydroxyapatite particles in a rat abdominal muscle pouch model published in Journal of Bone and Joint Infection.
Study published in Bone Joint Research
November 2022
TERM group at LU has published a study showing Extended Local Release and Improved Bacterial Eradication by Adding Rifampicin to a Biphasic Ceramic Carrier Containing Gentamicin or Vancomycin published in Bone Joint Research
EORS and International Combined Orthopedic Research Society Joint Meeting
September 2022
TERM group at LU presented their work at the recently held EORS and International Combined Orthopedic Research Society joint meeting.
Presentation: Enhanced Staphylococcus Aureus Antibiofilm Activity Without Resistance Development By Adding Rifampicin To A Biphasic Ceramic Carrier Containing Gentamicin Or Vancomycin.
NIRA Nomination for TERM group researcher
November 2021
Researcher from TERM group at Lu was nominated for the prestigious New Investigator Recognition Award (NIRA) for his work in bone infection.
Study published in BMC Musculoskeletal Disorders
September 2021
TERM group at LU has published a study reporting the different microbial and resistance patterns in primary total knee arthroplasty infections – a report on 283 patients from Lithuania and Sweden.
Selected publications and presentations
Play Video